MPE webinar on myeloma and AL amyloidosis treatment updates
Myeloma Patients Europe (MPE) will hold a webinar on myeloma and AL amyloidosis treatment updates on Wednesday 11 March 2020 from 18:30 – 19:30 CET.
Myeloma Patients Europe (MPE) will hold a webinar on myeloma and AL amyloidosis treatment updates on Wednesday 11 March 2020 from 18:30 – 19:30 CET.
Myeloma Patients Europe (MPE) held a webinar yesterday on ASH 2019 myeloma and AL amyloidosis highlights with the aim of reviewing the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019.
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019.
More than 900 myeloma abstracts (posters and oral sessions) were presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that was held from 7 to 10 December 2019 in Orlando, Florida, USA. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most…
ASH 2019, Orlando – New data presented by the HARMONY Alliance validate the current prognostic tool for Multiple Myeloma and have identified new parameters to improve the staging of the disease according to a press release publish by the Harmony Alliance. Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is…
More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7 to 10 December 2019 in Orlando, Florida, USA.
It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the drug daratumumab (Darzalex®, commercialised by Janssen).